Trial site
Diabetes and Thyroid Ctr of FW
Fort Worth, Texas 76132, United StatesNot linked to an institution yet
- 1running trial
- 7closed trials
The trials here
What the 8 trials at this site are about, from their registry records.
- Status
- Completed7 trials
- Not yet recruiting1 trial
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
NCT06340854· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
NCT06269107· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
NCT05352815· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
NCT05259033· Phase 3· Novo Nordisk A/S· Source
Completed
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· Phase 3· Novo Nordisk A/S· Source
Completed
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
NCT03914326· Phase 3· Novo Nordisk A/S· Source
Report an error